miR-155在甲状腺乳头状癌组织及血浆中的表达

The expression of miR-155 in carcinoma tissues and plasma of patients with papillary thyroid cancer

目的 :检测miR-155在甲状腺乳头状癌(papillary thyroid cancer,PTC)组织及血浆中的表达差异,评价其对PTC的诊断价值。方法:应用实时荧光定量聚合酶链式反应(real-time fluorescence quantitative polymerase chain reaction,RT-PCR)检测52例PTC、32例结节性甲状腺肿患者组织中miR-155的表达水平及对应患者血浆、30例同期于本院行体检健康者血浆miR-155表达水平。应用受试者工作曲线(ROC)分析血浆miR-155的诊断价值,并分析其在PTC血浆与癌组织中表达的相关性。结果:miR-155在PTC与结节性甲状腺肿组织中的相对表达量分别为8.43±6.14和1.14±0.41,PTC组高于结节性甲状腺肿组,差异有统计学意义(P<0.01)。PTC组、结节性甲状腺肿组、对照组血浆miR-155表达量分别为3.35±1.85、1.30±0.30和1.41±0.24,PTC组高于结节性甲状腺肿组及对照组,差异有统计学意义(P<0.01)。PTC组与对照组区分的ROC曲线下面积(AUC)为0.932(95%CI:0.851~0.970,P<0.001),PTC组与结节性甲状腺肿组区分的AUC为0.887(95%CI:0.811~0.961,P<0.001)。miR-155在PTC组织表达与血浆中的表达呈正相关(r=0.589,P<0.000 1)。其表达量与患者临床病理参数无相关性(P>0.05)。结论:PTC患者血浆中miR-155表达量升高,有可能成为一种新的血液学标志物用于PTC的诊断。

Objective:To investigate the expression of miR-155 in papillary thyroid cancer(PTC) tissue and plasma,and to evaluate the significance of plasma miR-155 level as a biomarker for PTC patients. Methods:Real-time fluorescence quantitative polymerase chain reaction was used to detect the change of miR-155 in tumor tissues and plasma of 52 PTC cases and 32 nodular goiter cases,as well as in plasma of 30 controls. Receiver operating characteristic(ROC) curves were drawn to evaluate the diagnostic threshold as well as the correlation between plasma miR-155 expression and tumorous tissue in PTC patients. Results:The average of miR-155 expression in PTC tumorous tissues and nodular goiter tissues was 8.43 ± 6.14 and 1.14 ± 0.41 respectively. The relative level of miR-155 in plasma of PTC and nodular goiter was 3.35 ± 1.85 and 1.41 ± 0.24,respectively. ROC curves for miR-155 to distinguish PTC and the control group yielded an AUC of 0.932(95%CI:0.851~0.970)(P < 0.001)and nodular goiter yielded an AUC of 0.887(95%CI:0.811~0.961)(P < 0.001). There was a positive correlation of miR-155 expression between plasma and tumorous tissue in PTC patients(r =0.589,P < 0.000 1). However,there was no relevance between the expression of plasma miR-155 and the clinical characteristics of the study population(P > 0.05). Conclusion:miR-155 expression is upregulated in patients with PTC. Plasma miR-155 may be used as a noninvasive biomarker for the prediction of papillary thyroid cancer.